These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15715463)

  • 1. Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.
    Marugán JJ; Manthey C; Anaclerio B; Lafrance L; Lu T; Markotan T; Leonard KA; Crysler C; Eisennagel S; Dasgupta M; Tomczuk B
    J Med Chem; 2005 Feb; 48(4):926-34. PubMed ID: 15715463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
    Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
    Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
    De Corte BL; Kinney WA; Liu L; Ghosh S; Brunner L; Hoekstra WJ; Santulli RJ; Tuman RW; Baker J; Burns C; Proost JC; Tounge BA; Damiano BP; Maryanoff BE; Johnson DL; Galemmo RA
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5227-32. PubMed ID: 15380233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5).
    Letourneau JJ; Liu J; Ohlmeyer MH; Riviello C; Rong Y; Li H; Appell KC; Bansal S; Jacob B; Wong A; Webb ML
    Bioorg Med Chem Lett; 2009 Jan; 19(2):352-5. PubMed ID: 19081719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
    Wendt JA; Wu H; Stenmark HG; Boys ML; Downs VL; Penning TD; Chen BB; Wang Y; Duffin T; Finn MB; Keene JL; Engleman VW; Freeman SK; Hanneke ML; Shannon KE; Nickols MA; Steininger CN; Westlin M; Klover JA; Westlin W; Nickols GA; Russell MA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):845-9. PubMed ID: 16303301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
    Boys ML; Schretzman LA; Chandrakumar NS; Tollefson MB; Mohler SB; Downs VL; Penning TD; Russell MA; Wendt JA; Chen BB; Stenmark HG; Wu H; Spangler DP; Clare M; Desai BN; Khanna IK; Nguyen MN; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Steininger CN; Westlin M; Westlin W; Yu YX; Wang Y; Dalton CR; Norring SA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):839-44. PubMed ID: 16298127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.
    Gentilucci L; Cardillo G; Spampinato S; Tolomelli A; Squassabia F; De Marco R; Bedini A; Baiula M; Belvisi L; Civera M
    J Med Chem; 2010 Jan; 53(1):106-18. PubMed ID: 20055426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suzuki-Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alphaVbeta3/alphaVbeta5 integrin antagonist. enantioselective synthesis and stereochemical studies.
    Kinney WA; Teleha CA; Thompson AS; Newport M; Hansen R; Ballentine S; Ghosh S; Mahan A; Grasa G; Zanotti-Gerosa A; Dingenen J; Schubert C; Zhou Y; Leo GC; McComsey DF; Santulli RJ; Maryanoff BE
    J Org Chem; 2008 Mar; 73(6):2302-10. PubMed ID: 18278942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
    Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
    Filzen GF; Bratton L; Cheng XM; Erasga N; Geyer A; Lee C; Lu G; Pulaski J; Sorenson RJ; Unangst PC; Trivedi BK; Xu X
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3630-5. PubMed ID: 17512197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
    Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
    Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and antifungal activity of isosteric analogues of benzoheterocyclic N-myristoyltransferase inhibitors.
    Sheng C; Xu H; Wang W; Cao Y; Dong G; Wang S; Che X; Ji H; Miao Z; Yao J; Zhang W
    Eur J Med Chem; 2010 Sep; 45(9):3531-40. PubMed ID: 20615585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.
    Ghosh S; Santulli RJ; Kinney WA; Decorte BL; Liu L; Lewis JM; Proost JC; Leo GC; Masucci J; Hageman WE; Thompson AS; Chen I; Kawahama R; Tuman RW; Galemmo RA; Johnson DL; Damiano BP; Maryanoff BE
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5937-41. PubMed ID: 15501072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
    Onda K; Shiraki R; Ogiyama T; Yokoyama K; Momose K; Katayama N; Orita M; Yamaguchi T; Furutani M; Hamada N; Takeuchi M; Okada M; Ohta M; Tsukamoto S
    Bioorg Med Chem; 2008 Dec; 16(23):10001-12. PubMed ID: 18952447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
    Skuli N; Monferran S; Delmas C; Favre G; Bonnet J; Toulas C; Cohen-Jonathan Moyal E
    Cancer Res; 2009 Apr; 69(8):3308-16. PubMed ID: 19351861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.
    Benfatti F; Cardillo G; Fabbroni S; Galzerano P; Gentilucci L; Juris R; Tolomelli A; Baiula M; Spartà A; Spampinato S
    Bioorg Med Chem; 2007 Dec; 15(23):7380-90. PubMed ID: 17869121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
    Gong Y; Barbay JK; Dyatkin AB; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Ballentine SA; Hageman WE; Masucci JA; Maryanoff BE; Damiano BP; Andrade-Gordon P; Hlasta DJ; Hornby PJ; He W
    J Med Chem; 2006 Jun; 49(11):3402-11. PubMed ID: 16722660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.